Mabion S.A.

Warsaw Stock Exchange MAB.WA

Mabion S.A. Return on Assets (ROA) for the year ending December 31, 2023: 19.82%

Mabion S.A. Return on Assets (ROA) is 19.82% for the year ending December 31, 2023, a 59.08% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Mabion S.A. Return on Assets (ROA) for the year ending December 31, 2022 was 12.46%, a 1,106.02% change year over year.
Mabion S.A. Return on Assets (ROA) for the year ending December 31, 2021 was 1.03%, a 101.41% change year over year.
Mabion S.A. Return on Assets (ROA) for the year ending December 31, 2020 was -73.02%, a -28.13% change year over year.
Mabion S.A. Return on Assets (ROA) for the year ending December 31, 2019 was -56.99%, a -19.75% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Warsaw Stock Exchange: MAB.WA

Mabion S.A.

CEO	Mr. Krzysztof Kaczmarczyk
IPO Date	Aug. 10, 2010
Location	Poland
Headquarters	ul. gen. Mariana Langiewicza 60
Employees	241
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics

Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Key trends

Past 5 years